Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China
· Delayed Price · Currency is CNY 21.56
+0.65 (3.11%)
May 16, 2025, 3:00 PM CST
Aurisco Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Operating Revenue | 1,538 | 1,472 | 1,254 | 1,001 | 800.46 | 717.74 | Upgrade
|
| Other Revenue | 3.67 | 3.67 | 8.59 | 7.23 | 2.9 | 3.7 | Upgrade
|
| Revenue | 1,542 | 1,476 | 1,263 | 1,008 | 803.36 | 721.44 | Upgrade
|
| Revenue Growth (YoY) | 18.99% | 16.89% | 25.24% | 25.48% | 11.36% | 24.04% | Upgrade
|
| Cost of Revenue | 633.77 | 631.38 | 564.22 | 495.51 | 408.64 | 381.12 | Upgrade
|
| Gross Profit | 908.34 | 844.36 | 698.32 | 512.57 | 394.72 | 340.32 | Upgrade
|
| Selling, General & Admin | 309.31 | 300.7 | 270.49 | 175.27 | 136 | 94.28 | Upgrade
|
| Research & Development | 149.5 | 146.34 | 136.89 | 117.26 | 69.35 | 47.35 | Upgrade
|
| Other Operating Expenses | 3.19 | 7.38 | 7.93 | 7.63 | 6.7 | 6.07 | Upgrade
|
| Operating Expenses | 468.57 | 457.96 | 419.48 | 304.36 | 211.96 | 148.44 | Upgrade
|
| Operating Income | 439.77 | 386.4 | 278.83 | 208.21 | 182.76 | 191.88 | Upgrade
|
| Interest Expense | -23.34 | -15.78 | -2.74 | -1.01 | -0.64 | - | Upgrade
|
| Interest & Investment Income | 13.96 | 18.31 | 48.25 | 4.41 | 8.94 | 7.82 | Upgrade
|
| Currency Exchange Gain (Loss) | 18.24 | 18.24 | 3.58 | 24.86 | -7.44 | -17.21 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.84 | -0.89 | -1.62 | -0.63 | 0.79 | -0.53 | Upgrade
|
| EBT Excluding Unusual Items | 446.8 | 406.28 | 326.31 | 235.84 | 184.41 | 181.96 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.84 | 2.25 | - | -1.19 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.09 | -0.41 | -1.53 | -1.5 | -0.4 | -0.26 | Upgrade
|
| Asset Writedown | -0.17 | -0.17 | - | - | - | -0.05 | Upgrade
|
| Other Unusual Items | -1.04 | -1.04 | 4.3 | 7.59 | 8 | 3.46 | Upgrade
|
| Pretax Income | 449.82 | 407.39 | 329.08 | 240.75 | 192.01 | 185.74 | Upgrade
|
| Income Tax Expense | 57.79 | 52.6 | 40.01 | 32.47 | 23.73 | 28.51 | Upgrade
|
| Earnings From Continuing Operations | 392.03 | 354.79 | 289.07 | 208.28 | 168.28 | 157.23 | Upgrade
|
| Minority Interest in Earnings | - | - | 0.35 | 2.69 | 0.43 | - | Upgrade
|
| Net Income | 392.03 | 354.79 | 289.42 | 210.96 | 168.71 | 157.23 | Upgrade
|
| Net Income to Common | 392.03 | 354.79 | 289.42 | 210.96 | 168.71 | 157.23 | Upgrade
|
| Net Income Growth | 20.35% | 22.59% | 37.19% | 25.04% | 7.31% | -15.53% | Upgrade
|
| Shares Outstanding (Basic) | 395 | 399 | 408 | 406 | 402 | 374 | Upgrade
|
| Shares Outstanding (Diluted) | 395 | 399 | 408 | 406 | 402 | 374 | Upgrade
|
| Shares Change (YoY) | -2.63% | -2.21% | 0.48% | 1.00% | 7.31% | 4.58% | Upgrade
|
| EPS (Basic) | 0.99 | 0.89 | 0.71 | 0.52 | 0.42 | 0.42 | Upgrade
|
| EPS (Diluted) | 0.99 | 0.89 | 0.71 | 0.52 | 0.42 | 0.42 | Upgrade
|
| EPS Growth | 23.60% | 25.35% | 36.54% | 23.81% | - | -19.23% | Upgrade
|
| Free Cash Flow | -239.26 | -207.87 | 80.13 | -49.82 | -49.04 | 55.68 | Upgrade
|
| Free Cash Flow Per Share | -0.60 | -0.52 | 0.20 | -0.12 | -0.12 | 0.15 | Upgrade
|
| Dividend Per Share | 0.290 | 0.290 | 0.220 | 0.160 | 0.130 | 0.120 | Upgrade
|
| Dividend Growth | 31.82% | 31.82% | 37.50% | 23.08% | 8.33% | 20.00% | Upgrade
|
| Gross Margin | 58.90% | 57.22% | 55.31% | 50.85% | 49.13% | 47.17% | Upgrade
|
| Operating Margin | 28.52% | 26.18% | 22.09% | 20.65% | 22.75% | 26.60% | Upgrade
|
| Profit Margin | 25.42% | 24.04% | 22.92% | 20.93% | 21.00% | 21.79% | Upgrade
|
| Free Cash Flow Margin | -15.52% | -14.09% | 6.35% | -4.94% | -6.11% | 7.72% | Upgrade
|
| EBITDA | 522.94 | 467.76 | 352.98 | 273.15 | 234.22 | 223.9 | Upgrade
|
| EBITDA Margin | 33.91% | 31.70% | 27.96% | 27.10% | 29.15% | 31.04% | Upgrade
|
| D&A For EBITDA | 83.16 | 81.36 | 74.15 | 64.94 | 51.47 | 32.02 | Upgrade
|
| EBIT | 439.77 | 386.4 | 278.83 | 208.21 | 182.76 | 191.88 | Upgrade
|
| EBIT Margin | 28.52% | 26.18% | 22.09% | 20.65% | 22.75% | 26.60% | Upgrade
|
| Effective Tax Rate | 12.85% | 12.91% | 12.16% | 13.49% | 12.36% | 15.35% | Upgrade
|
| Revenue as Reported | 1,542 | 1,476 | 1,263 | 1,008 | 803.36 | 721.44 | Upgrade
|
| Advertising Expenses | - | 56.72 | 33.73 | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.